2nd Dec 2015 10:37
LONDON (Alliance News) - Pharmaceutical research and development company Vernalis PLC said it remains confident on its prospects following a recent product launch and with further products in the pipeline.
The company, in a statement it will give to its annual general meeting, said the launch of Tuzistra XR, a codeine-based cough and cold syrup, in the US in September marked a milestone for the company and said it has another four cold programmes in active development with partner Tris Pharma Inc.
In addition, the group said it sees significant opportunities in the primary care market and, in October, expanded its portfolio with the acquisition of amoxicillin extended-release tablet brand Moxatag. The product will be re-launched in the first half of 2016.
Shares in Vernalis were up 3.3% to 72.30 pence on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Vernalis PLC